A state appeals court has decided that prescription drug manufacturers are bound to provide product warnings that exercise "due care," even if a generic equivalent is used to fill a prescription to which a patient has a negative reaction.

" A name-brand prescription drug manufacturer in disseminating product warnings owes a duty of care to patients who take a generic version of the drug pursuant to a prescription written in reliance on the name-brand maker's information," the court said...

Join our Membership to get the full story.


Are you a current Member? Sign In